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Coronary Computed Tomography
Angiography Compared With Single Photon
Emission Computed Tomography Myocardial
Perfusion Imaging as a Guide to Optimal
Medical Therapy in Patients Presenting With
Stable Angina: The RESCUE Trial
Arthur E. Stillman , MD, PhD; Constantine Gatsonis, PhD; Joao A.C. Lima , MD; Tao Liu, PhD;
Bradley S. Snyder, MS; Jean Cormack, PhD; Vinay Malholtra, MD; Mitchell D. Schnall, MD, PhD;
James E. Udelson, MD; Udo Hoffmann, MD, MPH; Pamela K. Woodard , MD; the RESCUE investigators*
BACKGROUND: The RESCUE (Randomized Evaluation of Patients with Stable Angina Comparing Utilization of Noninvasive
Examinations) trial was a randomized, controlled, multicenter, comparative efficacy outcomes trial designed to assess whether
initial testing with coronary computed tomographic angiography (CCTA) is noninferior to single photon emission computed
tomography (SPECT) myocardial perfusion imaging in directing patients with stable angina to optimal medical therapy alone
or optimal medical therapy with revascularization.
Downloaded from http://ahajournals.org by on August 10, 2021

METHODS AND RESULTS: The end point was first major adverse cardiovascular event (MACE) (cardiac death or myocardial infarction), or revascularization. Noninferiority margin for CCTA was set a priori as a hazard ratio (HR) of 1.3 (95% CI=0, 1.605).
One thousand fifty participants from 44 sites were randomized to CCTA (n=518) or SPECT (n=532). Mean follow-up time was
16.2 (SD 7.9) months. There were no cardiac-related deaths. In patients with a negative CCTA there was 1 acute myocardial
infarction; in patients with a negative SPECT examination there were 2 acute myocardial infarctions; and for positive CCTA
and SPECT, 1 acute myocardial infarction each. Participants in the CCTA arm had a similar rate of MACE or revascularization
compared with those in the SPECT myocardial perfusion imaging arm, (HR, 1.03; 95% CI=0.61-1.75) (P=0.19). CCTA segment
involvement by a stenosis of ≥50% diameter was a better predictor of MACE and revascularization at 1 year (P=0.02) than the
percent reversible defect size by SPECT myocardial perfusion imaging. Four (1.2%) patients with negative CCTA compared
with 14 (3.2%) with negative SPECT had MACE or revascularization (P=0.03).
CONCLUSIONS: There was no difference in outcomes of patients who had stable angina and who underwent CCTA in comparison to SPECT as the first imaging test directing them to optimal medical therapy alone or with revascularization. CCTA was a
better predictor of MACE and revascularization.
REGISTRATION INFORMATION: URL: https://www.clinicaltrials.gov/. Identifier: NCT01262625.
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■ nuclear medicine
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CLINICAL PERSPECTIVE
What Is New?

• This randomized, controlled, multicenter, comparative efficacy outcomes trial tested whether
initial testing with coronary computed tomographic angiography is noninferior to single photon emission computed tomography myocardial
perfusion imaging in directing patients with stable angina to optimal medical therapy alone or
optimal medical therapy with revascularization.
• Participants in the coronary computed tomographic angiography arm had similar rate of
major adverse cardiovascular events or revascularization compared with those in the single
photon emission computed tomography myocardial perfusion imaging arm.

What Are the Clinical Implications?

• This trial provides further evidence in support
of a coronary computed tomographic angiography first strategy for the diagnosis and management of patents presenting with symptoms of
stable angina.
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Nonstandard Abbreviations and Acronyms
OMT
ICA

I

optimal medical therapy
invasive coronary angiography

schemic heart disease is the main cause of morbidity and mortality worldwide, and will likely remain so
for at least the next decade.1,2 The goal in treating
patients with symptoms suggestive of stable ischemia
is to diagnose them in the most efficient way possible
in order to reduce their risk of death and myocardial
infarction.2,3 All patients with coronary artery disease
(CAD) with or without revascularization should be
treated with guideline-driven optimal medical therapy
(OMT).3,4 A number of trials,5–7 including the most recent
ISCHEMIA (International Study of Comparative Health
Effectiveness With Medical and Invasive Approaches)
trial,8 showed no evidence to suggest that an initial

invasive strategy, as compared with an initial conservative strategy, reduced the risk of ischemic cardiovascular events or death. Moreover, elective invasive
coronary angiography (ICA) in chronic stable angina
has been shown to be of low yield in many patients,9
and has the potential to directly increase the number
of unnecessary invasive catheter-based and surgical
revascularization procedures.10 Myocardial perfusion
by single photon emission computed tomography
myocardial perfusion imaging (SPECT-MPI) has been
the main noninvasive strategy used as a gatekeeper
to ICA and percutaneous coronary intervention, but its
effectiveness is low as an index of obstructive disease
by ICA.11
Coronary computed tomographic angiography
(CCTA), an anatomic imaging modality, is a potential
alternative to SPECT-MPI as the first line of testing in
patients with stable chest pain and suspected CAD,
and is now the recommended first line of testing in the
United Kingdom12,13 and in developing countries, where
the modality of CT is easily accessible and where morbidity and mortality caused by CAD is on the rise.12–15
In this trial we assess, in a head-to-head comparison, CCTA- and SPECT-MPI-driven imaging
algorithms.

METHODS
Requests to access the data set may be submitted
to the American College of Radiology (ACR) Center
for Research and Innovation (CRI) via https://dart.acr.
org.

Study Design
The RESCUE (Randomized Evaluation of Patients
with Stable Angina Comparing Utilization of
Noninvasive Examinations) Trial is a phase III, randomized, controlled, multicenter, comparative efficacy
study, designed to compare 2 diagnostic imaging/
treatment paradigms that use CCTA or SPECT-MPI
for assisting in the diagnosis of ischemic heart disease in patients with stable angina symptoms, and
guiding subsequent treatment (Figure 1A). Stable angina was defined as having Class I or II angina by the
Canadian Cardiovascular Society.16 The study design
was previously reported, to include the Consolidated

Figure 1. RESCUE (Randomized Evaluation of Patients with Stable Angina Comparing Utilization of Noninvasive
Examinations) Schema and Consolidated Standards of Reporting Trials (CONSORT) diagram.
A, Patients with symptoms of stable angina were randomized to receive either CCTA or SPECT-MPI. Diagnostic ICA was performed
in select patients according to the schema. All were followed for MACE/revascularization. B, CONSORT diagram. There were 1050
patients who were randomized (518 CCTA, 532 SPECT-MPI). CCTA was performed in 473 and SPECT-MPI was performed in 464.
There were 401 patients for CCTA and 378 patients for SPECT-MPI for evaluation of the secondary end point. CAD indicates coronary
artery disease; CCS, Canadian Cardiovascular Society; CCTA, coronary computed tomographic angiography; ICA, invasive coronary
angiography; LMD, Left main disease; MACE, major cardiovascular events; OMT, optimal medical therapy; and SPECT-MPI, single
photon emission computed tomography myocardial perfusion imaging.
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Standards of Reporting Trials flow diagram, which
we re-present in Figure 1B.17,18 The study protocol
was approved by the Institutional Review Boards at
each study site, or through a commercial Institutional

Review Board (Advarra Schulman). All patients provided written, informed consent. In the CCTA arm,
patients without left main disease were treated with
OMT. In the SPECT-MPI arm, patients with ≥10%
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reversible defect were directed to ICA, and patients
without left main disease by ICA were treated with
OMT. The Data Coordinating Center generated the
random allocation sequence and assigned participants to the 2 study arms in equal proportions.
Blocked randomization was used, stratified by sex
and participating institution. Randomization was
done at the time of study enrollment. All investigators and site coordinators involved in the trial were
blinded to randomization until after patient recruitment and assignment to the study arm (initial imaging
test). The site coordinators enrolled the participants.
The RESCUE (Randomized Evaluation of Patients
with Stable Angina Comparing Utilization of Noninvasive
Examinations) trial, funded by the Agency for Healthcare
Research and Quality and the American College
of Radiology Imaging Network Fund for Imaging
Innovation, began in 2011, and was completed in 2014.
Adherence to OMT was determined by patient follow-up.
Participants with positive cardiac-related findings on
their CCTA or SPECT/MPI were contacted at a minimum
of 4 time points (at 2 weeks and 2, 6, and 12 months).
Participants with negative findings on CCTA or SPECT
MPI were contacted at a minimum of 2 time points (6 and
12 months). Participants were then contacted every 6
months until the conclusion of the trial.18 The main funding mechanism was through the American Recovery
and Reinvestment Act. Unfortunately, this limited the
time possible for patient recruitment and follow-up. As
a result, the recruitment goal was not achieved which
limits the statistical power for data analysis.

Statistical Analysis
The primary aim of the study was to compare the
time-dependent rates of the composite primary end
point (major adverse cardiovascular event [MACE],
comprising cardiac-related death or acute myocardial infarctions [AMI], and revascularization) across
the 2 arms of the trial. Time to the primary end
point was measured from randomization to CCTA or
SPECT-MPI to the first occurrence of any of the component events. The primary analysis was conducted
from an intent-to-treat perspective, with time to event
compared between the CCTA and SPECT-MPI arms
using Kaplan-Meier curves with log-rank test. Cox
regression models were used to estimate the hazard
ratio to compare against the predefined noninferiority margin. The study was designed to achieve sufficient power with 4300 subjects in order to test the
noninferiority of CCTA compared with SPECT-MPI to
guide medical therapy, where the noninferiority margin was defined as a hazard ratio of 1.3 (95% CI=0,
1.605). The hazard ratio 1.3 margin was chosen in
that, given the projected sample size, it would provide 85% power.18

The RESCUE Trial

Secondary aims of the trial were (1) to evaluate the
ability of available prognostic indices to predict the
composite outcome status (MACE and revascularization) at 1 year, and (2) to develop a new predictive
index of composite outcome status at 1 year using
RESCUE data. For these secondary analyses, patients with <1-year follow-up (defined as <335 days)
were excluded from analysis, as were ineligible
patients and patients without the respective randomized scan or with an uninterpretable scan. The
ability of the Modified Duke Score from CCTA,19 and
percent reversible defect size on SPECT to predict
1-year composite outcome status were assessed
by receiver operating characteristic analysis, with
comparison by arm performed using the method of
DeLong.20
In developing a new predictive index, the
Modified Duke Score was replaced with a predictive model based upon the raw CCTA stenosis data. The American Heart Association (AHA)
16-segments were graded as being normal (0%),
very mild (1%–29%), mild (30%–49%), moderate
(50%–69%), or severe (≥70%) stenosis. Because
of the relatively few MACE events, these were
grouped to < 30%, 30%–49%, and ≥50% for subsequent analysis. A new index was derived using
the individual AHA 16-segment stenosis scores.
The association between each coronary artery
segment and composite outcome status at 1 year
was assessed using the exact χ 2 test (for categorical predictors), the nonparametric Wilcoxon
rank sum test (for continuous predictors), and
by the C-statistic from univariate logistic regression. Segment selection was performed using the
grouped least absolute selection and shrinkage
operator method 21 with tuning parameter identified using 5-fold cross-validation in order to limit
overfitting. Selected segments were then combined into an ordinary multivariate logistic regression model, with predictive ability of the new index
final model summarized using the C-statistic.
A P-value threshold of 0.05 was used to declare
statistical significance. Statistical analyses were performed using SAS 9.4 (SAS Institute) or R software
(version 3.3.1; R project, http://www.r-project.org).

RESULTS
Our study was designed to enroll and randomize 4300
participants to the 2 study arms, but given the difficulties of recruiting enough patients to fulfill the stringent
entry criteria, as well as time constraints for funding
(American Recovery and Reinvestment Act award,
3-year cap), we recruited one quarter of the planned
sample size.
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Between May 2011 and April 2013, 1050 participants from 44 sites were enrolled and randomized in
a 1:1 ratio to either CCTA or SPECT-MPI. Of the 1050
participants, 3 were placed off-study, because of a
duplicate registration (n=1), site Institutional Review
Boards closure (n=1), and lack of informed consent
(n=1). Demographics and CAD risk factors of the remaining 1047 participants are shown in Table S1.
Details of the participant flow through the trial are illustrated in the Consolidated Standards of Reporting
Trials diagram shown in Figure 1B.
Among the 1047 eligible participants, 110 (10.5%)
participants did not have the randomized scan for
reasons shown in Table S2. We continued to follow
these 110 participants according to the study protocol. Since an intention-to-treat analysis was performed, these 110 participants were included in the
analysis of the primary aim. Mean follow-up time
for all patients in the trial was 16.2 (SD 7.9) months.
Imaging status with types of events is shown in
Table S3. There were no cardiac-related deaths observed in the study. There was 1 AMI for patients
with negative CCTA, and 2 AMI for patients with a
negative SPECT examination. There was 1 AMI each
for patients with positive CCTA and SPECT examinations. Among patients with negative CCTA examinations, 4/345 (1.2%) had MACE or revascularization,
whereas 14/436 (3.2%) patients with negative SPECT
examinations had MACE or revascularization (logrank P=0.03). A total of 25/122 (20.5%) patients
with positive CCTA had MACE or revascularization,
whereas 8/23 (34.8%) patients with positive SPECT
had MACE or revascularization (log rank P=0.24).
There were 169 (32.8%) patients in the CCTA arm
who had incidental findings, 59 of whom required
follow-up imaging. In the SPECT MPI arm there were
only 9 (1.7%) patients who had incidental findings, 2
of whom required follow-up imaging.
Participants in the CCTA arm had a similar rate of
experiencing the primary end point compared with
those in the SPECT-MPI arm, with a hazard ratio estimate of 1.03 (95% CI, 0.61–1.75). (P=0.19).
Imaging-associated adverse events were uncommon in the trial (Table S4), with only 1 adverse event
with an attribution of probable or definite in the CCTA
arm that was judged to be moderate or greater in
severity. There were no reported adverse events with
attribution of probable or definite in the SPECT arm.
In the trial overall, there were 10 reported deaths, of
which none were determined to be cardiac (7 malignancy, 1 stroke, 1 cocaine drug overdose, and 1
pulmonary end-stage chronic obstructive pulmonary
disease).
Of the 145 patients with positive cardiac-related
findings on their CCTA or SPECT/MPI, 128 patients
could be contacted at 6 months, 118 at 12 months, 88
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at 18 months, and 47 at 24 months. Of the 781 patients
with negative findings on CCTA or SPECT MPI, 654
could be contacted at 6 months, 618 at 12 months,
391 at 18 months, and 253 at 24 months. Adherence
to OMT in patients with a positive examination, including adherence to medical therapy (antihypertensives,
medication for diabetes mellitus, and blood thinners)
and nonsmoking was described by 44 (34.4%) of the
128 patients who could be contacted at 6 months.
Information regarding adherence to OMT is provided
in Table S5.
A total of 401 patients were analyzed for CCTA and
a total of 378 patients were analyzed for SPECT for
purposes of the secondary end points. Relevant exclusions are shown in Figure 1B. The derived Modified
Duke Scores are shown in Table S6. The ability of the
Modified Duke Score and percent reversible defect
size on SPECT-MPI to predict composite outcome
status (MACE and revascularization) at 1 year was assessed by receiver operating characteristic analysis
(Figure 2). While the Modified Duke Score had a higher
area under the curve (area under the curve=0.87,
95% CI, 0.81–0.94) than the percent reversible defect
size (area under the curve=0.73, 95% CI, 0.59–0.88),
this difference did not achieve statistical significance
(P=0.08), likely because of the relatively few MACE and
revascularization events.
In addition to assessing the prognostic ability of the
Modified Duke Score on CCTA and percent reversible
defect size on SPECT-MPI, a secondary aim for the trial
was to develop a new index from the RESCUE data
for prediction of composite outcome status at 1 year.
The results from univariate logistic regression models
assessing the predictive ability of each of the individual AHA 16-arterial segments are shown in Table S7.
The C-statistic corresponds to the receiver operating
characteristic area under the curve using the predicted
values from the univariate regression model and gives
a measure of strength of each predictor. The proximal
and mid-left anterior descending artery segments exhibited the largest C-statistics and were the only arterial segments selected by the least absolute selection
and shrinkage operator. The new CCTA model using
only these 2 segments resulted in significantly better
discriminatory ability for the composite outcome than
the SPECT percent reversible defect size (P=0.02,
Figure 3).

DISCUSSION
In the RESCUE trial, there was no difference in outcomes of patients who had stable angina and who
underwent CCTA in comparison to SPECT as the first
imaging test directing them to OMT alone or with revascularization. CCTA was a better predictor of MACE
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Figure 2. Receiver operating characteristic curves show a trend towards improved prediction of
the composite end point of major cardiovascular events and revascularization at 1 year using the
modified Duke score compared with percent reversible defect.
AUC indicates area under the curve; CCTA, coronary computed tomographic angiography; and SPECT,
single photon emission computed tomography.

and revascularization. These findings are consistent
with the findings of the recently published ISCHEMIA
trial,8 which showed no evidence that an initial invasive strategy, as compared with an initial conservative
strategy, reduced the risk of ischemic cardiovascular
events. In the ISCHEMIA trial, patients with an unprotected left main stenosis of at least 50% diameter as
determined by CCTA were excluded.8 RESCUE also
excluded patients with left main disease as determined
by either CCTA or ICA.
Thus, ISCHEMIA showed and RESCUE suggests
that CCTA can be effectively used to direct patients
to either revascularization (patients with left main disease) and OMT, or OMT alone. Under the ISCHEMIA/
RESCUE paradigm, CT fractional flow reserve would be
required only in the assessment of left main disease.
However, the accuracy of computational fluid dynamics

methods to estimate fractional flow reserve by CCTA
makes the case for use of CCTA more compelling.22,23
Like RESCUE, the PROMISE (Prospective
Multicenter Imaging Study for Evaluation of Chest Pain)
trial14 showed more frequent revascularization in patients who underwent CCTA in comparison to SPECT,
and there was also a trend towards increased revascularization for CCTA compared with standard care in
the SCOT-HEART (Scottish Computed Tomography
of the Heart) trial,24 although it did not reach statistical
significance. While one may wonder whether these revascularizations benefited the patient, fewer AMI and
coronary heart disease deaths were found in the CCTA
arm of SCOT-HEART, suggesting that CCTA was better at identifying patients who ultimately benefitted from
revascularization. In RESCUE, CCTA was a better predictor of MACE and revascularization. Previous trials
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Figure 3. Proximal and LAD segments for CCTA were significantly better predictors for the
composite end point of major adverse cardiovascular event and revascularization than percent
reversible defect (Rdefect).
AUC indicates area under the curve; CCTA, coronary computed tomographic angiography; LAD, left
anterior descending artery; and SPECT, single photon emission computed tomography.

such as the COURAGE (Clinical Outcomes Utilizing
Revascularization and Aggressive Drug Evaluation),6
BARI-2D (Bypass Angioplasty Revascularization
Investigation 2 Diabetes),7 and ORBITA (Objective
Randomized Blinded Investigation With Optimal
Medical Therapy of Angioplasty in Stable Angina)5 trials,
while they did not specifically address CCTA, also support the hypothesis that patients with stable angina and
CAD other than left main disease could be successfully
treated by OMT alone, with mortality outcomes similar
to those of patients who had interventions. Regarding
the modified Duke score, as with RESCUE, Min et al
found that the modified Duke score with CCTA provided
prognostic information regarding MACE.19 Both methods provide a measure of the myocardium at risk.25

The results of RESCUE should be interpreted in
the context of certain limitations. Limitations of the
RESCUE trial include modest adherence rates to
OMT. In RESCUE, adherence rates for OMT were
comparable in the 2 groups at just below 39% over
the follow-up period. This is significantly less than
COURAGE,26 in which adherence to OMT was 80%
at 5 years and ISCHEMIA, where adherence to OMT
ranged from 73.9% to 81.5%, but comparable to adherence rates in a real-life setting.27 In COURAGE and
ISCHEMIA, higher OMT adherence rates were most
likely secondary to not only the regularly scheduled
nurse manager visits, but also the provision of medications or some medications at no cost to the patient.8,26
In RESCUE, power was decreased by reducing the
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sample size from 4300 to 1050 patients, event rates
were lower than expected suggesting mild-to-moderate ischemic disease, and the period of follow-up was
modest, at an average of 16.2 months. The power of
the study may have also affected the results of the
secondary aims.
The findings in RESCUE do not apply to patients
with acute coronary syndromes, low ejection fraction,
or heart failure. Patients with left main disease and
continued symptomatology despite patient-described
adherence to OMT were directed to revascularization.
In conclusion, we compared treatment paradigms
with initial imaging with CCTA to initial imaging with
SPECT-MPI in directing patients with stable angina to
OMT alone or OMT with revascularization and, within
the limitations described above, found no difference
in patient outcomes. Findings suggest that CCTA is a
better predictor of MACE and revascularization.

APPENDIX
RESCUE Investigators
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Table S1. Demographics and CAD Risk factors
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Category

Value

CCTA Analyzed*
(N=516)

SPECT Analyzed*
(N=531)

AGE - YR

MEAN
RANGE

57(SD=9)
40-85

58(SD=9)
40-86

BMI**

MEAN

30 (SD=5)

29 (SD=5)

RANGE

16-41

17-43

RACE

AMERICAN INDIAN OR ALASKA
ASIAN
BLACK OR AFRICAN AMERICAN
NATIVE HAWAIIAN OR OTHER
WHITE
MULTIPLE RACE ENDORSEMENT
UNKNOWN

8(2%)
11(2%)
73(14%)
2(<1%)
400(78%)
10(2%)
12(2%)

7(1%)
14(3%)
77(15%)
1(<1%)
415(78%)
5(1%)
12(2%)

ETHNICITY

HISPANIC OR LATINO
NOT HISPANIC OR LATINO
UNKNOWN

46(9%)
467(91%)
3(1%)

58(11%)
468(88%)
5(1%)

SEX

FEMALE
MALE

233(45%)
283(55%)

244(46%)
287(54%)

CCSS ANGINA**

CLASS I
CLASS II
CLASS III

297(58%)
183(35%)
33(6%)

305(57%)
181(34%)
35(7%)

CARDIAC RISK**+

CAD, ACS OR AMI FEMALE <65 YEARS AGE
DIABETES MELLITUS
DIAGNOSIS OF CAD, ACS OR AMI MALE <55 YEARS
DYSPNEA
HAVE YOU SMOKED CIGARETTES, EVEN A PUFF,
IN THE PAST 30 DAYS
HYPERCHOLESTEROLEMIA/HYPERLIPIDEMIA
HYPERTENSION
PRIOR HISTORY OF CAD
TRIGLYCERIDEMIA

73(14%)
105(20%)
136(26%)
257(50%)
74(14%)

74(14%)
114(21%)
125(24%)
258(49%)
87(16%)

324(63%)
318(62%)
57(11%)
114(22%)

313(59%)
317(60%)
55(10%)
121(23%)

* 3 Participants were taken off-study, and are not included in the analysis set
** 1034/1047 participants submitted data on the relevant case report form
+ Participants may endorse multiple risk factors

2

Table S2. Reasons randomized scan not performed

Arm
Reason
Equipment
Ineligible
Insurance
Medical
Participant
Scheduling
Unknown
Total

CCTA SPECT
2
0
0
1
1
7
15
14
22
38
2
3
1
4
43
67

Total
2
1
8
29
60
5
5
110

Table S3. Imaging status by MACE and revascularization outcome

Scan Not Performed

Missing

Un-interpretable

Endpoint

Scan

Negative Scan
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No
AMI Revasc. Event

Positive Scan

No
No Event

AMI

No Event

Total

No

AMI Revasc. Event AMI Revasc. Event

N

CCTA
0

0

43

0

0

6

1

3

341

1

24

97

516

3

1

63

1

1

3

2

12

422

1

7

15

531

3

1

106

1

1

9

3

15

763

2

31

112

1047

SPECT

Total

3

Table S4. Imaging-associated Adverse Events

ARM
CCTA

Grade

SPECT

Relation to Study Procedure

Total

Relation to Study Procedure

Unrelated Unlikely Possible Probable Definite

Total

Unrelated Unlikely Possible Probable Definite

Total

N

Mild

0

1

3

0

0

4

1

0

0

0

0

1

5

Moderate

2

0

0

0

1

3

0

2

0

0

0

2

5

Severe

3

0

0

0

0

3

2

0

0

0

0

2

5

Life threatening

0

0

0

0

0

0

1

0

0

0

0

1

1

Fatal

0

0

0

0

0

0

0

0

0

0

0

0

Total

5

1

3

0

1

4

2

0

0

0

6

10
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0
16

Table S5. Patient adherence to OMT
Group
All Cases
All Cases
All Cases
All Cases
All Cases

Follow-up Compliant
6m
44
12m
45
18m
39
24m
19
Total
147

CCTA Cases
CCTA Cases
CCTA Cases
CCTA Cases
CCTA Cases

6m
12m
18m
24m
Total

SPECT Cases
SPECT Cases
SPECT Cases
SPECT Cases
SPECT Cases

6m
12m
18m
24m
Total

N
128
118
88
47
381

Percent
34.4
38.1
44.3
40.4
38.6

39
37
31
16
123

108
97
74
40
319

36.1
38.1
41.9
40.0
38.6

5
8
8
3
24

20
21
14
7
62

25.0
38.1
57.1
42.9
38.7
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Table S6. CCTA Modified Duke Score

Modified Duke prognostic score

N

%

(1) <50% stenosis

287

71.6%

(2) >=2 stenoses 30-49% (including 1 artery w/ proximal disease) or 1
vessel w/ 50-69% stenosis

44

11.0%

(3) 2 stenoses 50-69% or 1 vessel w/ >=70% stenosis

28

7.0%

(4) 3 stenoses 50-69% or 2 vessels w/ >=70% stenosis or proximal left
anterior descending stenosis >=70%

28

7.0%

(5) 3 vessels >=70% stenoses or 2 vessels >=70% stenosis w/ proximal
left anterior descending

6

1.5%

(6) Left main stenosis >=50%

8

2.0%

Total

401

5

100.0%

Table S7. Results of univariate logistic regression models, summarizing the
ability of individual AHA 16-arterial segments to predict composite outcome
status (MACE and revascularization) at 1 year.

Predictor

C-statistic
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LAD mid

0.86

LAD proximal

0.76

RCA mid

0.71

LAD distal

0.69

LAD diagonal 1

0.68

LCX proximal

0.68

RCA distal

0.63

LAD diagonal 2

0.62

RPDA

0.61

RCA proximal

0.59

LCX obtuse marginal 2

0.59

LCX distal

0.59

Left main

0.57

Ramus

0.57

LCX obtuse marginal 1

0.57

LPDA

0.50

6

